ISSN:
1569-8041
Keywords:
chemotherapy
;
HBV carrier
;
hepatitis B
;
malignant lymphoma
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background: Hepatitis B after the withdrawal of cytotoxicchemotherapy in hepatitis B virus (HBV) carriers is well known and may leadto fatal hepatic failure. We retrospectively analyzed the prevalence of HBVcarriers, the incidence, and the risk factors of hepatitis B in the treatmentof malignant lymphoma. Patients and methods: HBV carriers were defined as patients withpositive HBs-antigen, either with normal or abnormal serum aminotransferaselevel at patient presentation. Questionnaires to the members of the JapanLymphoma Treatment Study Group included general information, details about HBVcarriers, and further information about hepatitis B. Results: Among 1380 patients collected from eight institutions, 45patients (3.26%) were determined to be HBV carriers. Hepatitis Bdeveloped in 17 of the HBV carrying patients (37.8%). Seven of those17 (41.2%) died of hepatic failure. Hepatitis developed at a high ratein patients who were negative for HBe-antigen (50%), and who hadreceived second- or third-generation chemotherapy (63.2%). Conclusion: We confirmed that hepatitis B developed with highfrequency in HBV carriers with malignant lymphoma. Moreover, hepatitis oftenresulted in fatal hepatic failure. It is necessary to prevent the hepatitisB developing in HBV carriers when receiving intensive chemotherapy formalignant lymphoma.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008234807768
Permalink
